+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia Pacific Colorectal Cancer Screening Market Size, Share & Industry Trends Analysis Report By Type (Colonoscopy, Stool-based (Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), and Stool-DNA Test), By End-user, By Country and Growth Forecast, 2023 - 2030

  • PDF Icon

    Report

  • 134 Pages
  • August 2023
  • Region: Asia Pacific
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5886875
The Asia Pacific Colorectal Cancer Screening Market should witness market growth of 5.7% CAGR during the forecast period (2023-2030).

Colorectal Cancer (CRC) happens when cancerous cells begin to develop and spread in the colon or rectum part of the digestive tract. Early cases can have no symptoms and begin with non-cancerous polyps' growth but can be found with screening testing. A colorectal cancer screening detects the disease in asymptomatic individuals over 45 at a high risk of developing the disease. The size and site of the cancer affect the CRC's symptoms. Significant disease symptoms include alterations in bowel habits, stool consistency, blood in the stool, and abdominal pain. The need for screening to enable early detection and treatment of the disease has grown due to the rising incidence of CRC.

Colorectal cancer is also termed colon or rectal cancer. Colon and rectal cancer diagnostics are researched and developed along the same lines as these are different merely on the basis of origin of cancer. Over the past decade, there has been an increase in colorectal cancer cases, which can be ascribed to lifestyle diseases, an aging population, and improper dietary habits.

According to GLOBOCAN statistics, China is expected to have 286,162 deaths attributable to colorectal cancer (CRC) and 555,477 new disease cases in 2020. In recent years, China has seen an increase in the disease burden of CRC, particularly in urban and eastern regions, due to population aging, socioeconomic development, and lifestyle changes. Due to rising disposable incomes throughout the region, there is a greater awareness of colorectal cancer. The market for colorectal cancer screening is expected to expand due to the region's rising prevalence and expanding awareness of the disease.

The China market dominated the Asia Pacific Colorectal Cancer Screening Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1.6 billion by 2030. The Japan market is anticipated to grow at a CAGR of 5% during (2023-2030). Additionally, India's market should witness a CAGR of 6.3% during (2023-2030).

Based on Type, the market is segmented into Colonoscopy, Stool-based (Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), and Stool-DNA Test), and Others. Based on End-user, the market is segmented into Government, Energy, Defense, Agriculture & Forestry, Media & Entertainment, Civil Engineering & Archaeology, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novigenix SA, Eiken Chemical Co., Ltd., Clinical Genomics Pathology, Inc., Exact Sciences Corporation, Epigenomics AG, BioMerieux S.A., Olympus Corporation, Sysmex Corporation, Fujifilm Holdings Corporation, and Siemens Healthineers AG (Siemens AG).

Scope of the Study

By Type

  • Colonoscopy
  • Stool-based
    • Fecal Immunochemical Test (FIT)
    • Fecal Occult Blood Test (FOBT)
    • Stool-DNA Test
  • Others

By End-user

  • Hospitals & Clinics
  • Clinical Laboratories
  • Diagnostic Imaging Centres
  • Others

By Country

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

  • Novigenix SA
  • Eiken Chemical Co., Ltd.
  • Clinical Genomics Pathology, Inc.
  • Exact Sciences Corporation
  • Epigenomics AG
  • BioMerieux S.A.
  • Olympus Corporation
  • Sysmex Corporation
  • Fujifilm Holdings Corporation
  • Siemens Healthineers AG (Siemens AG)

Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Colorectal Cancer Screening Market, by Type
1.4.2 Asia Pacific Colorectal Cancer Screening Market, by End-user
1.4.3 Asia Pacific Colorectal Cancer Screening Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Geographical Expansions
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Mergers & Acquisition: 2019, Jul - 2022, Dec) Leading Players
4.4 Porter’s Five Forces Analysis
Chapter 5. Asia Pacific Colorectal Cancer Screening Market by Type
5.1 Asia Pacific Colonoscopy Market by Country
5.2 Asia Pacific Stool-based Market by Country
5.3 Asia Pacific Colorectal Cancer Screening Market by Stool-based Type
5.3.1 Asia Pacific Fecal Immunochemical Test (FIT) Market by Country
5.3.2 Asia Pacific Fecal Occult Blood Test (FOBT) Market by Country
5.3.3 Asia Pacific Stool-DNA Test Market by Country
5.4 Asia Pacific Others Market by Country
Chapter 6. Asia Pacific Colorectal Cancer Screening Market by End-user
6.1 Asia Pacific Hospitals & Clinics Market by Country
6.2 Asia Pacific Clinical Laboratories Market by Country
6.3 Asia Pacific Diagnostic Imaging Centres Market by Country
6.4 Asia Pacific Others Market by Country
Chapter 7. Asia Pacific Colorectal Cancer Screening Market by Country
7.1 China Colorectal Cancer Screening Market
7.1.1 China Colorectal Cancer Screening Market by Type
7.1.1.1 China Colorectal Cancer Screening Market by Stool-based Type
7.1.2 China Colorectal Cancer Screening Market by End-user
7.2 Japan Colorectal Cancer Screening Market
7.2.1 Japan Colorectal Cancer Screening Market by Type
7.2.1.1 Japan Colorectal Cancer Screening Market by Stool-based Type
7.2.2 Japan Colorectal Cancer Screening Market by End-user
7.3 India Colorectal Cancer Screening Market
7.3.1 India Colorectal Cancer Screening Market by Type
7.3.1.1 India Colorectal Cancer Screening Market by Stool-based Type
7.3.2 India Colorectal Cancer Screening Market by End-user
7.4 South Korea Colorectal Cancer Screening Market
7.4.1 South Korea Colorectal Cancer Screening Market by Type
7.4.1.1 South Korea Colorectal Cancer Screening Market by Stool-based Type
7.4.2 South Korea Colorectal Cancer Screening Market by End-user
7.5 Singapore Colorectal Cancer Screening Market
7.5.1 Singapore Colorectal Cancer Screening Market by Type
7.5.1.1 Singapore Colorectal Cancer Screening Market by Stool-based Type
7.5.2 Singapore Colorectal Cancer Screening Market by End-user
7.6 Malaysia Colorectal Cancer Screening Market
7.6.1 Malaysia Colorectal Cancer Screening Market by Type
7.6.1.1 Malaysia Colorectal Cancer Screening Market by Stool-based Type
7.6.2 Malaysia Colorectal Cancer Screening Market by End-user
7.7 Rest of Asia Pacific Colorectal Cancer Screening Market
7.7.1 Rest of Asia Pacific Colorectal Cancer Screening Market by Type
7.7.1.1 Rest of Asia Pacific Colorectal Cancer Screening Market by Stool-based Type
7.7.2 Rest of Asia Pacific Colorectal Cancer Screening Market by End-user
Chapter 8. Company Profiles
8.1 Novigenix SA
8.1.1 Company Overview
8.1.2 SWOT Analysis
8.2 Eiken Chemical Co., Ltd.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.3 Clinical Genomics Pathology, Inc.
8.3.1 Company Overview
8.3.2 Recent strategies and developments:
8.3.2.1 Partnerships, Collaborations, and Agreements:
8.3.3 SWOT Analysis
8.4 Exact Sciences Corporation
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Acquisition and Mergers:
8.4.6 SWOT Analysis
8.5 Epigenomics AG
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 SWOT Analysis
8.6 BioMerieux S.A.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Acquisition and Mergers:
8.6.6 SWOT Analysis
8.7 Olympus Corporation
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Partnerships, Collaborations, and Agreements:
8.7.5.2 Product Launches and Product Expansions:
8.7.5.3 Acquisition and Mergers:
8.7.6 SWOT Analysis
8.8 Sysmex Corporation
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.8.5 SWOT Analysis
8.9 Siemens Healthineers AG (Siemens AG)
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.9.4.1 Acquisition and Mergers:
8.9.5 SWOT Analysis
8.10. Fujifilm Holdings Corporation
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental and Regional Analysis
8.10.4 Research & Development Expenses
8.10.5 Recent strategies and developments:
8.10.5.1 Partnerships, Collaborations, and Agreements:
8.10.5.2 Product Launches and Product Expansions:
8.10.5.3 Geographical Expansions:
8.10.6 SWOT Analysis

Companies Mentioned

  • Novigenix SA
  • Eiken Chemical Co., Ltd.
  • Clinical Genomics Pathology, Inc.
  • Exact Sciences Corporation
  • Epigenomics AG
  • BioMerieux S.A.
  • Olympus Corporation
  • Sysmex Corporation
  • Fujifilm Holdings Corporation
  • Siemens Healthineers AG (Siemens AG)

Methodology

Loading
LOADING...